<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01256905</url>
  </required_header>
  <id_info>
    <org_study_id>C10953/6268</org_study_id>
    <nct_id>NCT01256905</nct_id>
  </id_info>
  <brief_title>Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies</brief_title>
  <acronym>Armodafinil</acronym>
  <official_title>Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>New York University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if a drug commonly used to treat excessive day-time
      sleepiness, called armodafinil (Nuvigil), is also effective in improving the impairment in
      the attention commonly reported by patients with more advanced Parkinson's disease (PD) and
      Lewy body disease (LBD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main aims of this study are:

      1. To investigate whether in PDD and DLB th specific disturbances in the basal ganglia
      thalamocortical network, measured through the Electroencephalography (EEG) frequency
      analysis, are ameliorated by armodafinil.

      Our main hypothesis is that armodafinil can restore the attention and improve cognitive
      disturbances in PDD and DLB, through a specific effect on striatal-thalamo-cortical activity.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <primary_completion_date type="Anticipated">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EGI netstation software (Electrical Geodesics Inc.) and a custom made software that runs on the Matlab platform (The Mathworks)</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Parkinsons Disease</condition>
  <condition>Lewy Bodies Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Armodafinil</intervention_name>
    <description>Armodafinil 150 mg</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established criteria for diagnosis of PDD (Parkinsons Disease) {Emre M et al. Mov
             Disord 2007;22:1689-707} and DLB (Lewy Bodies Disease) {McKeith et al. Neurology
             2005;65:1863-72}

          -  Mini Mental State Examination (MMSE) score between &lt;24; and/or Dementia Rating

          -  Scale-2 (DRS-2) score &lt;134;

          -  Clinical Assessment of Fluctuation (CAF)&gt;4;

          -  Stable anti-parkinsonian medication in the 4 weeks preceding the study

        Exclusion Criteria:

          -  Use of cognitive enhancers (Donepezil, Rivastigmine, Galantamine, Modafinil,
             Memantine) in the last 4 weeks:

        Concomitant use of any medication contraindicated with modafinil/armodafinil; History of
        alcohol and substances abuse. Use of medications known to alter the normal EEG activity in
        humans during the study period (i.e. clonazepam) History of psychiatric disorders, other
        than depression and psychiatric complication of PDD and DLB
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Varanese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Parkinsons and Movement Disorders Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Varanese, M.D.</last_name>
    <phone>212-263-4838</phone>
    <phone_ext>3</phone_ext>
    <email>sara.varanese@nyumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jamika Y. Singleton-Garvin</last_name>
    <phone>212-263-7042</phone>
    <email>Jamika.Singleton-Garvin@nyumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NYU Parkinsons and Movement Disorders Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Varanese, M.D.</last_name>
      <phone>212-263-4838</phone>
      <phone_ext>3</phone_ext>
      <email>sara.varanese@nyumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Jamika Y Singleton-Garvin</last_name>
      <phone>212-263-7042</phone>
      <email>Jamika.Singleton-Garvin@nyumc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sara Varanese, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://parkinson.med.nyu.edu/</url>
    <description>armodafinil</description>
  </link>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <last_update_submitted>December 8, 2010</last_update_submitted>
  <last_update_submitted_qc>December 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sara Varanese, M.D.</name_title>
    <organization>NYU Parkinsons and Movement Disorders Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Armodafinil</mesh_term>
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

